Pharmacological therapy in age-related macular degeneration (AMD)

International Journal of Ophthalmology

Volumn 5, Issue 1, 2005, Pages 8-18

  Zou, Yan Hong ^a   Chiou, George C Y ^a  

^a Department of Neuroscience and Experimental Therapeutics   (United States)

Author keywords

Age related macular degeneration; Anecortave acetate; Choroidal blood flow; PDT; Pharmacological therapy; VEGF

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ALPHA TOCOPHEROL; ANECORTAVE; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ARGINYLGLYCYLASPARTIC ACID; ASCORBIC ACID; BENZOPORPHYRIN DERIVATIVE; BETA CAROTENE; CAROTENOID; DEXAMETHASONE; GELATINASE A; GELATINASE B; HYDROCORTISONE DERIVATIVE; HYDROXAMIC ACID DERIVATIVE; LIPOSOME; MATRIX METALLOPROTEINASE 14; PARVOVIRUS VECTOR; PIGMENT EPITHELIUM DERIVED FACTOR; PLACEBO; POLYVINYL ALCOHOL; RETINOL; STEROID; THALIDOMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; XANTHOPHYLL; ZEAXANTHIN; ZINC;

ARTICLE; BLINDNESS; BRUCH MEMBRANE; CATARACT; CLINICAL TRIAL; DIET SUPPLEMENTATION; EXTRACELLULAR MATRIX; GENE THERAPY; GLAUCOMA; HUMAN; INDUSTRIALIZATION; INTRAOCULAR PRESSURE; LASER COAGULATION; MEDICAL DECISION MAKING; META ANALYSIS; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; RAT; RETINA BLOOD FLOW; RETINA MACULA AGE RELATED DEGENERATION; RETINA PIGMENT DEGENERATION; RETINA SURGERY; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; TRANSPUPILLARY THERMOTHERAPY; TREATMENT OUTCOME; UNITED STATES;

EID: 16844364533     PISSN: 16725123     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study [J]. Ophthalmology, 1992;99:933-943
2. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The blue Mountains Eye Study [J]. Ophthalmology, 1995;102:1450-1460
3. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial [J]. Arch Ophthalmol, 1991;109:1220-1231
4. Macular Photocoagulation Study Group. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy [J]. Arch Ophthalmol, 1986;104:503-512
5. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity [J]. Arch Ophthalmol, 1994;112:480-488
6. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study [J]. Arch Ophthalmol,1991;109: 1242-1257
7. Ip M, Kroll A, Reichel E. Transpupillary thermotherapy for age-related macular degeneration: long-pulse photocoagulation, apoptosis, and heat shock proteins [J]. Ophthalmic Surg lasers, 2000;31:359-373
8. Hooper CY, Guymer RH. New treatments in age-related macular degeneration [J]. Clin Experiment Ophthalmol, 2003;31(5):376-391
9. The Radiation Therapy for Age-related Macular Degeneration Study Group. A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study) [J]. Ophthalmolgy, 1999;106:2239-2247
10. Vingerling J, Dielemans I, Bots M, Hofman A, Grobbee D, De Jong P. Age-related macular degeneration is associated with atherosclerosis: the Rotterdam Study [J]. Am J Epidemiol, 1995;142:404-409
11. Ferris III FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy [J]. Arch Ophthalmol, 1984;102: 1640-1642
12. Mozaffarieh M, Sacu S, Wedrich A. The role of the carotenoids, lutein and zeaxanthin, in protecting against age-related macula degeneration: a review based on controversial evidence [J]. Nutr J, 2003;2:20
13. Hammond BR Jr, Johnson EJ, Russell RM, Krinsky NI, Yeum KJ, Edwards RB, Snodderly DM. Dietary modification of human macular pigment density [J]. Invest Ophthalmol Vis Sci, 1997;38:1795-1801
14. Berendschot TT, Goldbohm RA, Klopping WA, van de Kraats J, van Norel J, van Norren D. Influence of lutein supplementation on macular pigment, assessed with two objective techniques [J]. Invest Ophthalmol Vis Sci ,2000; 41: 3322-3326
15. Johnson EJ, Hammond BR, Yeum KJ, Qin J, Wang XD, Castaneda C, Snodderly DM, Russell RM. Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density [J]. Am J Clin Nutr, 2000;71:1555-1562
16. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers [J]. N Engl J Med, 1994; 330: 1029-1035
17. Peterson K. 'Natural' cancer prevention trial halted [J]. Science ,1996; 271:441-442
18. AREDS report No.8. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss [J]. Arch Ophthalmol, 2001;119:1417-1436
19. Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K, Tsipursky M, Nyland J. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST Study (Lutein Antioxidant Supplementation Trial) [J]. Optometry 2004;75(4):216-230
20. Amabati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies [J]. Surv Ophthalmol, 2003;48:257-293
21. Zacks DN, Earz E, Terada Y, Michaud N, Connolly E, Gragoudas ES, Miller JW. Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: angiographic and histologic characterization [J]. Invest Ophthalmol Vis Sci, 2002;43:2384-2391
22. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy [J]. Invest Ophthalmol Vis Sci , 2003;44 (5): 2147-2154
23. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin. One year results of two randomized clinical trials-TAP report 1 [J]. Arch Ophthalmol, 1999;117:1329-1345
24. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin. Two years results of two randomized clinical trials-TAP report 2 [J]. Arch Ophthalmol, 2001;119: 198-207
25. Vertrporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularisation in age-related macular degeneration: two year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularisation-veteporfin in photodynamic therapy report 2 [J]. Am J Ophthalmol 2001;131:541-560
26. Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, Ma C, Menchini U, Miller J, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Strong HA, Stur M, Su XY, Virgili G. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report No. 1 [J]. Am J Ophthalmol, 2003;136 (3):407-418
27. Bessler NM, VAM Study Writing Committee. Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4435 patients [J]. Retina, 2004;24:512-520
28. Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, Zografos L, Piguet B, Pournaras CJ, Donati G, Lane AM, Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macula degeneration. Results of retreatments in a phase 1 and 2 study [J]. Arch Ophthalmol , 1999;117: 1161-1173
29. Hopley C, Salkeld G, Mitchell P. Cost utility of photodynamic therapy for predominatly classic neovascular age related macular degeneration [J]. Br J Ophthalmol, 2004;88:982-987
30. Edelman JL, Castro MR. Quantitative image analysis of laser-induced choroidal neovascularization in rat [J]. Exp Eye Res, 2000;71:523-533
31. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model [J]. Arch Ophthalmol, 2001;119:399-404
32. Kaven C, Spraul CW, Zavazava N, Lang GK, Lang GE. Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro [J]. Ophthalmologica, 2001;215:284-289
33. Danis RP, Ciulla TA, Pratt LM. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration [J]. Retina 2000;20:244-250
34. Miller H, Miller B, Ryan SJ. The role of retinal pigment epithelium in the involution of subretinal neovascularization [J]. Invest Ophthalmol Vis Sci, 1986;27:1644-1652
35. Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate [J]. Arch Ophthalmol, 1985;103:708-711
36. Ranson NT, Danis Rp, Ciulla TA, Pratt L. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration [J]. Br J Ophthalmol, 2002;86:527-529
37. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration [J]. Br J Ophthalmol, 2004;88:344-347
38. Gillies M, Simpson J, Chua W, Cherepanoff S, Billson F, Mitchell P, Hunyor A. The efficacy and safety of a single intravitreal injection of triamcinolone for neovascular age-related macular degeneration. One year results of a randomised clinical trial: IVTAS[J]. Clin Exp Ophthalmol, 2002;30 (suppl.):A64
39. Przydryga J, Duzee B, Robertson S. Anecortave acetate: pharmacology of a unique ocular angiostatic agent [J]. Clin Exp Ophthalmol, 2002;30(Suppl):A66
40. Penn JS, Rajaratnam VS, Collier RJ, Clark AF. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity [J]. Invest Ophthalmol Vis Sci, 2001;42:283-290
41. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, Robertson SM, Russell S, Singerman L, Slakter JS, Yannuzzi L, Zilliox P. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes[J]. Ophthalmology, 2003;110:2372-2383
42. Augustin AJ, D'Amico DJ, Mieler WF, Schneebaum C, Beasley C. Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration [J]. Graefes Arch Clin Exp Ophthalmol, 2004;28:[Epub ahead of print]
43. Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes [J]. Am J Ophthalmol, 1996;122: 393-403
44. Lopez PF, Sippy BD, lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes [J]. Invest Ophthalmol Vis Sci, 1996;37:855-868
45. Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, Ferrara N, Adamis AP. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate [J]. Ophthalmology, 1996;103:1820-1828
46. Baffi J, Byrnes G, Chan CC, Csaky KG. Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor [J]. Invest Ophthalmol Vis Sci 2001;42:s227
47. Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization [J]. Am J Pahtol, 2000;157:135-144
48. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O'Neill CA, Miller JW. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment [J]. Arch Ophthalmol, 2002;120: 338-346
49. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration [J]. Retina, 2002;22:143-152
50. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results [J]. Ophthalmology, 2003;110:879-881
51. Berglin L, Sarman S, van der Ploeg I, Steen B, Ming Y, Itohara S, Seregard S, Kvanta A. Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2-deficient mice [J]. Invest Ophthalmol Vis Sci, 2003;44:403-408
52. Yasukawa T, Hoffmann S, Eichler W, Friedrichs U, Wang YS, Wiedemann P. Inhibition of experimental choroidal neovascularization in rats by an alpha(v)-integrin antagonist [J]. Curr Eye Res, 2004;28:359-366
53. Kohri T, Moriwaki M, Nakajima M, Tabuchi H, Shiraki K. Reduction of experimental laser-induced choroidal neovascularization by orally administered BPHA, a selective metalloproteinase inhibitor [J]. Graefes Arch Clin Exp Ophthalmol, 2003;241(11):943-952
54. Koh HJ, Bessho K, Cheng L, Bartsch DU, Jones TR, Bergeron-Lynn G, Freeman WR. Inhibition of choroidal neovascularization in rats by the urokinase-derived peptide A6 [J]. Invest Ophthalmol Vis Sci,2004;45(2): 635-640
55. Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, Nguyen QD, Sung JU. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD) [J]. Hum Gene Ther 2001;12(16):2029-2032
56. Kimura H, Yasukawa T, Tabata Y, Ogura Y, Drug targeting to choroidal neovascularization [J]. Advanced Drug Delivery Reviews, 2001;52:79-91
57. Renno RZ, Terada Y, Haddadin MJ, Michaud NA, Gragoudas ES, Miller JW. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2 [J]. Arch Ophthalmol,2004; 122:1002-1011
58. Ciulla TA, Criswell MH, Danis RP, Fronheiser M, Yuan P, Cox TA, Csaky KG, Robinson MR. Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants [J]. Br J Ophthalmol, 2003;87:1032-1037
59. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration [J]. Am J Ophthalmol, 2004;137(3):486-495
60. Age-related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-related Eye Disease Study Report No.3 [J]. Ophthalmology, 2000;107:2224-2232
61. Hyman L, Schachat AP, He Q, Leske MC. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-related Macular Degeneration Risk Factor. Study Group [J]. Arch Ophthalmol ,2000;118: 351-358
62. Friedman E. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration [J]. Am J Ophthalmol , 2000;130: 658-663
63. Friedman E. Update of the vascular model of AMD [J]. Br J Ophthalmol, 2004;88:161-163
64. Sippy BD, Hinton DR. Aging of retina and retinal pigment epithelium. In: Age-Related Mecular Degeneration [M]. Lim JI Ed. New York: Marcel Dekker, 2002:1-14
65. Yoken J, Duncan JL, Berger JW. Laser photocoagulation for choroidal neovascularization in AMD. In : Age-Related Mecular Degeneration [M]. Lim JI Ed. New York: Marcel Dekker, 2002:181-201
66. Flaxel CJ, Finger P. Radiation treatment in AMD. In: Age-Related Mecular Degeneraation [M]. Lim JI ed. New York: Marcel Dekker,2002: 225-238
67. Rogers AH, Martidis A, Reichel E. Transpupillary thermotherapy of subfoveal occult choroidal neovascularization. In : Age-Related Mecular Degeneraation [M]. Lim JI ed. New York:Marcel Dekker,2002:259-265
68. Rao PK, Thomas MA. Submacular surgery for patients with AMD. In : Age-Related Mecular Degeneration [M]. Lim JI ed. New York: Marcel Dekker,2002:277-288
69. AuEong KG, Fuji GY, Pieramici DJ. Limited macular tranlocation. In : Age-Related Mecular Degeneration [M]. Lim JI ed. New York: Marcel Dekker, 2002:289-318
70. McCabe FJ, Ho AC. Argon laser to Drusen. In : Age-Related Mecular Degeneration [M]. Lim JI ed. New York: Marcel Dekker,2002:325-342
71. Friberg TR. Treatment of nonexudative AMD with infrared (810nm) diode laser photocoagulation. In : Age-Related Mecular Degeneraation [M]. Lim JI Ed. New York: Marcel Dekker,2002:343-354
72. Blumenkranz MS, Woodburn KW. Photodynamic therapy. In : Age-Related Mecular Degeneration [M]. Lim JI ed. New York: Marcel Dekker,2002: 203-224
73. Campochiaro PA, Kane FE. Choroidal neovascularization. In : Age-Related Mecular Degeneration [M]. Lim JI ed. New York: Marcel Dekker, 2002:267-276